{"id":"W3137447968","doi":"10.1200/jco.20.03175","title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Gastroenterology; Refractory (planetary science); Follicular lymphoma; Lymphoma; Rituximab; Adverse effect; CD20; Alemtuzumab; Oncology; T cell; Immunology; Immune system; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01296793,0.0003229704,0.002680075,0.0005304338,0.0001784643,0.00004956509,0.0004210974,0.0007482478,0.003099527],"category_scores_gemma":[0.01589971,0.0002385572,0.0008948226,0.0009527451,0.0003041443,0.0001702769,0.000216167,0.003278981,0.00003957582],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007590653,"about_ca_system_score_gemma":0.009032334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004031485,"about_ca_topic_score_gemma":0.00002275706,"domain_scores_codex":[0.9903271,0.002378209,0.004807657,0.000600286,0.001121412,0.000765394],"domain_scores_gemma":[0.9844342,0.01085221,0.002304085,0.0005396844,0.0009294188,0.0009403929],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1589805,0.03203849,0.001714551,0.0001627403,0.0002284978,0.01080312,0.0003649379,0.00001363151,0.7414843,0.000007578538,0.004853024,0.04934863],"study_design_scores_gemma":[0.5129048,0.02436674,0.001736446,0.0006824234,0.0002910532,0.001211099,0.00224428,0.0006677249,0.01300595,0.00005160444,0.4424855,0.0003523663],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980907,0.001909403,0.0001347108,0.006260362,0.002631015,0.0005699631,0.00001134436,0.00002383802,0.007552407],"genre_scores_gemma":[0.9791636,0.005144499,0.005942306,0.001105571,0.003075272,0.00001000969,0.00002413299,0.00007525072,0.005459333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7284784,"threshold_uncertainty_score":0.9990205,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2659444738081362,"score_gpt":0.5123547411190288,"score_spread":0.2464102673108926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}